TW201613651A - Pharmaceutical composition containing polymerized camptothecin derivative and polymerized hsp90 inhibitor derivative - Google Patents

Pharmaceutical composition containing polymerized camptothecin derivative and polymerized hsp90 inhibitor derivative

Info

Publication number
TW201613651A
TW201613651A TW104105731A TW104105731A TW201613651A TW 201613651 A TW201613651 A TW 201613651A TW 104105731 A TW104105731 A TW 104105731A TW 104105731 A TW104105731 A TW 104105731A TW 201613651 A TW201613651 A TW 201613651A
Authority
TW
Taiwan
Prior art keywords
polymerized
derivative
drug
pharmaceutical composition
camptothecin derivative
Prior art date
Application number
TW104105731A
Other languages
Chinese (zh)
Inventor
Manami Okazaki
Sakiko Maruyama
Akira Masuda
Keiichiro Yamamoto
Original Assignee
Nippon Kayaku Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Kayaku Kk filed Critical Nippon Kayaku Kk
Publication of TW201613651A publication Critical patent/TW201613651A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/40—Polyamides containing oxygen in the form of ether groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/48—Polymers modified by chemical after-treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

To provide a cancer chemotherapy drug exhibiting a strong antitumor effect. Specifically, to provide a cancer chemotherapy drug exhibiting a stronger antitumor effect, by using a polymerized camptothecin derivative which is a camptothecin derivative functioning as a key drug in cancer chemotherapy. An antitumor pharmaceutical composition which combines a polymerized camptothecin derivative and a polymerized derivative of a 1,2,4-triazole-3-one-substituted resorcinol derivative having an HSP90 inhibitor activity, and is to be administered so as to deliver the two derivatives simultaneously, sequentially, or with an interval interposed therebetween. These two polymerized drug derivatives make it possible to improve drug efficacy, reduce toxicity to normal cells, and selectively deliver pharmacological activity to a tumor site, by efficiently delivering the drug to and releasing the drug in the affected area.
TW104105731A 2014-02-19 2015-02-17 Pharmaceutical composition containing polymerized camptothecin derivative and polymerized hsp90 inhibitor derivative TW201613651A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014029049 2014-02-19

Publications (1)

Publication Number Publication Date
TW201613651A true TW201613651A (en) 2016-04-16

Family

ID=53878147

Family Applications (1)

Application Number Title Priority Date Filing Date
TW104105731A TW201613651A (en) 2014-02-19 2015-02-17 Pharmaceutical composition containing polymerized camptothecin derivative and polymerized hsp90 inhibitor derivative

Country Status (3)

Country Link
JP (1) JP6461088B2 (en)
TW (1) TW201613651A (en)
WO (1) WO2015125641A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180039628A (en) 2015-09-03 2018-04-18 니폰 가야꾸 가부시끼가이샤 A pharmaceutical composition containing a camptothecin analog derivative
AU2017226131A1 (en) * 2016-03-01 2018-10-04 Nippon Kayaku Kabushiki Kaisha Pharmaceutical preparation containing camptothecin-based polymeric derivative
CN112279863A (en) * 2019-07-25 2021-01-29 华东师范大学 Conjugate of Hsp90 inhibitor and camptothecin derivative as well as preparation method and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1580216E (en) * 2002-10-31 2014-07-31 Nippon Kayaku Kk High-molecular weight derivatives of camptothecins
JP5548364B2 (en) * 2006-10-03 2014-07-16 日本化薬株式会社 Polymer conjugates of resorcinol derivatives
JP2014532712A (en) * 2011-11-02 2014-12-08 シンタ ファーマシューティカルズ コーポレーション Cancer therapy using a combination of a topoisomerase I inhibitor and an HSP90 inhibitor

Also Published As

Publication number Publication date
JPWO2015125641A1 (en) 2017-03-30
WO2015125641A1 (en) 2015-08-27
JP6461088B2 (en) 2019-01-30

Similar Documents

Publication Publication Date Title
MX2023000320A (en) Methods of modulating drug plasma levels using erythrohydroxybupropion.
CL2016001629A1 (en) Tricyclic compounds as anticancer agents
AU2018201942B2 (en) Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
WO2014145642A3 (en) Nrf2 small molecule inhibitors for cancer therapy
MX2020012924A (en) Treatment of cancer using coenzyme q10 combination therapies.
NZ749218A (en) Androgen receptor modulator and uses thereof
WO2016161342A3 (en) Nitrobenzyl derivatives of anti-cancer agents
WO2012159085A3 (en) Compositions and methods for treating and preventing cancer by targeting and inhibiting cancer stem cells
MX2015010791A (en) Methods of treating cancer and preventing drug resistance.
MD4643B1 (en) Novel indolizine derivatives, method for the production thereof and pharmaceutical compositions containing same
AR097619A1 (en) USE OF ACETIL-COA CARBOXYLASE INHIBITORS TO TREAT ACNÉ VULGARIS
PH12016500863A1 (en) Tetracyclic autotaxin inhibitors
RU2018135973A (en) PHARMACEUTICAL COMBINATION CONTAINING METROFORMIN AND DYHYDROQUERCENINE, AND ITS APPLICATION FOR TREATING CANCER
WO2013134407A3 (en) Procaspase 3 activation by combination therapy
EP3162804A8 (en) New benzodiazepine derivative and use thereof
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
UA117581C2 (en) Low-dose antitumor agent including irinotecan hydrochloride hydrate
NZ716765A (en) Pharmaceutical combinations for the treatment of cancer
MX2016015568A (en) Nucleoside derivatives for the treatment of cancer.
MX2022000394A (en) Therapeutic combinations of orally administered paclitaxel and a p-gp inhibitor for the treatment of cancer.
TW201613651A (en) Pharmaceutical composition containing polymerized camptothecin derivative and polymerized hsp90 inhibitor derivative
MX2017015532A (en) Pac-1 combination therapy.
MX370957B (en) Compound of the avermectin family or of the milbemycin family for the treatment and/or prevention of atopic dermatitis.
NZ712584A (en) Antitumor agent including irinotecan hydrochloride hydrate
WO2016191703A3 (en) Tumor deliverable iron and protein synthesis inhibitors as a new class of drugs for the diagnosis and treatment of cancer